Since September 2024 a pharmaceutical import licence here goes only to an applicant who can show export earnings and clear the Foreign Exchange Supervisory Committee. A medicines distributor is therefore judged on something that has nothing to do with medicine: whether it has a demonstrable route to foreign currency. Everything else about a candidate is secondary to that, and most briefs never ask.
The demand side has shifted decisively private, and quickly. Households seeking care from private providers rose from about a third to nearly three fifths between 2021 and 2023, while those seeking no formal care at all fell from over half to under a fifth. Out-of-pocket spending was close to three quarters of total health spending, and public health allocation fell to around two and a half per cent of the union budget. Pharmacies are now described as the primary distribution channel.
The supply side is almost entirely imported. Estimates of the import share run from eighty to ninety per cent according to which source you take, and the local manufacturing base is small — the manufacturers’ association lists single figures of member companies across a handful of sites. Import value figures conflict badly: four published series for overlapping years differ by an order of magnitude, which is why no single market size appears on this page.
What governs access is not demand and not registration. It is currency. Since September 2024 a pharmaceutical import licence has been issued only where the applicant can show export earnings and has cleared the Foreign Exchange Supervisory Committee, a body reconstituted in August 2025 under the prime minister with explicit authority over foreign currency for medicine imports. A distributor that cannot obtain dollars cannot import, however good its relationships are.
That sits on top of a multiple exchange rate system that moves margin away from the importer. There is an official peg that has been unchanged for years, an online platform rate well above it, and an unofficial market rate above that again. In one documented episode importers were told they would get a licence only if they bought dollars at the official rate while the market sat far higher; medicine prices rose up to a quarter inside a month.
The chain has five gates, and they are sequential. The product is registered with the FDA. The importer obtains a Drug Importation Approval Certificate. It must be a member of the pharmaceutical chamber, which also reviews the licence application the Department of Trade forwards to it. The Ministry of Commerce then licenses the shipment. Only then does the currency committee decide whether the dollars exist. In August 2024 the Department of Trade deleted 716 pending pharmaceutical applications from 116 companies, worth over a hundred million dollars, and required all of them to be refiled with proof of export earnings.
The second thing worth understanding is that the import certificate is built around a specific inspected building. The application asks for warehouse dimensions, written storage practice with photographs, and a video of the storage system — and the certificate is explicitly not transferable between importers. There is no separate distribution-practice certificate to inspect. The warehouse assessment is inside the import permission, which means the premises you walk and the premises on the certificate had better be the same one.
Three recognisable groups make up the channel. The first is the healthcare arm of a diversified family conglomerate — a unit inside a group that also does food, retail or finance, able to draw on group balance sheet and, importantly, on group export earnings. The second is the pharma-plus-consumer distribution house running branches and sub-dealers across the country. The third is the device and hospital equipment importer, usually tender-led and project-led.
Nothing in the available sources indicates a regulator-mandated multi-agent structure or a state-appointed agent. The channel is privately owned and relationship-driven, and in devices increasingly tender-driven where international agencies and medical charities are the buyers. That means your leverage is commercial rather than regulatory, which cuts both ways: nothing forces a second importer on you, and nothing protects you from a single one.
Published coverage claims are exactly that. Several houses describe branch and dealer networks, warehouse counts, cold chain since a given year, and coverage percentages in the nineties; all of it is self-reported. The independent evidence points the other way. Public hospitals concentrate in Yangon and Mandalay, regions and states largely lack their own warehouses so suppliers deliver direct to hospitals, and distributors reported difficulty reaching conflict-affected areas and moved to third-party couriers as costs rose.
Foreign ownership of a distribution entity is permitted. Wholesale and retail trading was opened to wholly foreign-owned companies and joint ventures, with minimum initial investment thresholds that fall substantially where a Myanmar partner holds meaningful equity, and the permitted goods list expressly includes medicines, medical products and hospital equipment. Whether a foreign-owned entity can in practice clear the currency gate, which rewards companies with Myanmar export earnings, is not something we could establish either way.
Five gates, sequentially. Each has a document, and the second one — the import certificate — is the one most briefs never ask to see.
The currency question comes first because it decides whether the rest is worth doing. Then the import certificate, because it is the document that binds a distributor, a product list and a building together.
Bank statements and credit advices showing foreign currency received for exports, or evidence of purchasing export earnings from an exporter, or central bank platform purchase records. Then ask for the currency committee approval references on the last three approved licences, with dates, and compute the real cycle.
It must be current and in the candidate’s own name, and it carries the registered products it covers. If your category is not on it, your first shipment is at least the certificate lead time plus a licence cycle away, and that is the honest launch date.
The application required dimensions, written practice with photographs and a storage video. Those files exist — ask for them. Then verify ambient control, cold chain capability with monitoring records if you need it, and that the premises you are shown is the premises on the certificate.
It is a listed document for the import certificate and the chamber reviews licence applications. A lapsed membership stops imports, and it lapses quietly. Ask for the current certificate rather than a statement that they are members.
A company may file one application per month per customs code. A distributor importing the same codes for several principals is rationing your shipments against theirs. Ask which codes they file under, for whom, and how many applications have auto-cancelled at the hundred-and-eighty-day mark.
Renewal is refused where annual fees are unpaid for two consecutive years, and imported registered products undergo laboratory testing every five years. Ask for the fee receipts and the test result, and note which named employee signature sits on file with the regulator.
The import certificate is not transferable, and the registration certificate goes to the resident authorised representative. The variation process covers changes to a product’s details, not a change of representative. Get a written undertaking to support re-registration in a successor’s name.
Screen beneficial owners against the main designation lists, and establish which bank carries your payment. Then ask for customs clearance dates against bill of lading dates on the last five consignments, and whether they use bonded warehouse entry, which medicines are eligible for.
In August 2024 a Department of Trade letter deleted seven hundred and sixteen pharmaceutical import licence applications from a hundred and sixteen companies, worth over a hundred million dollars, from the trade system. All had to be refiled with proof of export earnings, and the manufacturers’ association said no detailed directives explained how to prove it.
The import certificate is explicitly non-transferable between importers, and the registration certificate is handed only to the resident authorised representative. A distributor switch stops imports until the incoming party holds its own certificate — around three months on the official timeline, plus a licence cycle.
Because the certificate is built on premises dimensions, storage photographs and a storage video, moving premises or appointing a party whose physical storage differs from the certificate creates a documentation mismatch at the point of clearance rather than a logistics inconvenience.
Permit processing that took about two weeks before 2021 now takes months and can be refused outright, with importers reporting waits of two to five months and goods accruing demurrage at port. Container import dwell time has risen from about four and a half days to nearly sixteen.
Exporters must convert a share of earnings at the official rate, and importers who do not export must buy earnings from those who do. The arithmetic can mean a distributor sells at a loss on paper, and the documented response is to raise prices or to stop carrying the line.
Currency depreciation drove price increases across drug categories of thirty per cent to two hundred, with some brands unavailable for two weeks to six months in a single year. Nearly four fifths of households reported medicine price rises in a six-month window, and a majority of hypertensive households cut back or skipped doses on cost.
You need a Myanmar-registered entity. Registration applications must be made by an authorised representative resident in Myanmar, and the certificate is handed only to that representative. The import certificate additionally requires incorporation, an exporter and importer registration held by a locally established company’s headquarters, and chamber membership. You may own that entity, subject to the capital thresholds for foreign-owned wholesale.
No. Myanmar’s own notified procedure states that licences are not transferable between importers. For the product registration, no transfer mechanism for medicines appears in the available sources — the variation process covers changes to the drug’s details, not a change of representative. Budget for a new import certificate, around three months officially, plus a licence cycle, and assume a supply gap.
Drug registration is reported at six to twelve months. The import certificate issues in about three months. The import licence takes around thirty working days and must be issued before the goods arrive. Currency committee approval sits on top with no published timetable. Twelve to eighteen months from appointment to first commercial shipment is a realistic planning assumption.
Not as a standalone instrument that we could locate. What exists instead is a storage and distribution assessment embedded inside the import certificate application: warehouse dimensions, written storage and distribution practice with photographs, and a video of the storage system. That makes the distribution-quality requirement specific to one inspected building rather than portable between premises.
On paper, yes. Wholesale trading is open to wholly foreign-owned companies and joint ventures with minimum initial investment thresholds, lower where a Myanmar partner holds meaningful equity, and the permitted goods list expressly includes medicines, medical products and hospital equipment. Whether a foreign-owned entity can clear the foreign currency gate in practice is undocumented.
No medicine-specific restriction appears in any source we checked. The constraints are counterparty and channel: two state banks are designated, two more are flagged for close scrutiny, the country sits on the financial action task force blacklist, and official advisories warn about structures routed through neighbouring jurisdictions and against relying on unsupported assurances. Fix the banking route and screen ownership before signing.
We would rather tell you early that a market is not currently workable than build you a shortlist that cannot pay. The currency question comes first here and we answer it first. Tell us what you are considering and we will come back on that before anything else.
How we verify How a distributor search runs